FDA places hold on MacroGenics’ bispecific antibody trials over liver toxicity concerns

Two trials involving the drug MGD009 – a monotherapy study and one in combination with the company’s PD-1 inhibitor – are barred from enrolling new patients pending FDA review and a planned protocol amendment.

Article Source: FDA places hold on MacroGenics’ bispecific antibody trials over liver toxicity concerns.